

MMP Consultation on Best-Value Biological Medicine – Adalimumab 20 mg

The HSE-Medicines Management Programme (MMP) has previously undertaken a review of biological medicines containing adalimumab that are available on the High Tech Arrangement, focusing on presentations of adalimumab that are predominately used in adult patients. Arising from this, best-value biological (BVB) medicines have been identified for presentations of adalimumab 40 mg solution for injection that are available in self-administered injection devices i.e. pre-filled pens and syringes.¹

The MMP is now seeking to identify a BVB medicine(s) for presentations of adalimumab 20 mg solution for injection that are available in self-administered injection devices i.e. pre-filled pen/pre-filled syringe. These presentations of adalimumab are predominately used in paediatric patients.

The identification of the BVB medicine(s) will be carried out in accordance with the evaluation process outlined in the *MMP roadmap for the prescribing of best-value biological medicines*:

<https://www.hse.ie/eng/about/who/cspd/ncps/medicines-management/best-value-biological-medicines/mmp-roadmap-for-the-prescribing-of-best-value-biological-bvb-medicines-in-the-irish-healthcare-setting.pdf>.

This process is limited to medicinal products that are available on the High Tech Arrangement as of 11th December 2020.

As part of this evaluation process, the MMP is undertaking a consultation process. Submissions are invited from all relevant stakeholders, and should be emailed to mmp@hse.ie by 5pm on Thursday 28th January 2021.

References

1. HSE-Medicines Management Programme. Best-value biological medicines.

<https://www.hse.ie/eng/about/who/cspd/ncps/medicines-management/best-value-biological-medicines/>